AUSTIN, Texas--(BUSINESS WIRE)--CEDRA Corporation, a division of Worldwide Clinical Trials, announced today that it has purchased the Gyrolab™ xP workstation for use in its bioanalytical research, specifically for ligand binding analysis. CEDRA is employing the new Gyrolab in its Ligand Binding Assay (LBA) laboratory in Austin, Texas, and is the only CRO in North America to offer this technology to the pharmaceutical industry.
